Hepatitis C in Drug and Alcohol Settings

Saturday 6 November 2021, 9.30am - 12.30pm

Target Audience 

Addiction medicine physicians, general practitioners, nurse practitioners, and other practitioners prescribing or intending to prescribe s85 DAA medication for HCV in alcohol and other drug settings in Australia.

Learning Outcomes 

By the end of this training, participants will be able to: 

• Describe risk factors for HCV, enabling discussions with clients around prevention and harm reduction
• Screen, order and interpret tests appropriately to diagnose chronic HCV infection
• Perform the recommended pre-treatment assessment, including liver disease staging
• Determine the appropriate antiviral therapy for treatment of HCV and explain treatment to patient
• Implement monitoring and post-treatment follow-up recommendations

This course will be delivered in three parts

Part 1 consists of a 1.5-hour eLearning component introducing the learner to assessment, management and treatment of hepatitis C in drug and alcohol settings.

Part 2 consists of a 3-hour interactive online training session building on the knowledge and skills gained in Part 1 through practical case discussions.

Part 3 consists of a tailored capacity strengthening toolkit including: a checklist for the assessment and treatment of HCV in drug and alcohol settings; local referral pathways; Fibroscan® access forms; assessment pro forma; and quick reference guides.